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Although various pharmacologic agents are under active study [1], there are currently no effective 
and evidence-based antiviral drugs or drug combinations against severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) infection, namely coronavirus disease 2019 (COVID-19). 
Therefore, supportive therapy and active treatment of COVID-19 clinical manifestations by using 
feasible and currently available agents, especially Food and Drug Administration (FDA)-approved 
drugs, still remains an essential therapeutic approach [2-4].  
To this regard, great interest has risen with respect to the potential beneficial effects against 
COVID-19 of drugs that are currently used for cardiovascular prevention [3,5]. Indeed, although 
the main clinical manifestations of COVID-19 involve the respiratory system, an increased risk of 
cardiovascular complications, including myocarditis, cardiac arrhythmias, and arterial and venous 
thrombosis, has been reported in COVID-19 patients [6-8]. In addition, underlying cardiovascular 
diseases (CVDs) and/or cardiovascular risk factors (e.g., smoking, diabetes, obesity) have been 
associated with an increased risk of severe clinical complications and death in COVID-19 patients 
[6-12]. 
Whether statins may be re-purposed to treat COVID-19 patients is a matter of debate. There are 
several points that are worthy of being considered in support of possible beneficial effects of statins 
against COVID-19. First, statins are widespread, available, low-cost, and safe cholesterol-
lowering drugs, that have been extensively demonstrated to reduce significantly CVD risk [13,14]. 
Each mmol/l reduction in LDL-cholesterol (LDL-C) reduces the risk of major cardiovascular 
events by about one quarter for each year statin therapy is continued [13,14]. Therefore, it is likely 
that statins may also mitigate CVD risk in COVID-19 patients. Second, due to their cholesterol-
lowering activity and their pleiotropic effects, statins can inhibit inflammation, immune response, 
and oxidative stress [15-17], exert direct antiviral effects [18], improve endothelial function [19-
21], and regulate hemostasis [22,23], potentially reducing the incidence of severe clinical 
manifestations and improving prognosis in COVID-19 patients. This latter point will be discussed 
in more depth in the following text. 
Statins may conceivably protect against inflammation by controlling cytokine overexpression and 
modulating immune responses [15,16], thereby potentially preventing the development of acute 
distress respiratory syndrome (ARDS) and reducing the incidence of cardiovascular complications 
in COVID-19 patients. Indeed, statins have been shown to directly inhibit nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) (Figure 1), which is a crucial mediator of 
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inflammatory responses during infections, including those caused by coronaviruses [24]. In 
addition, they have been reported to negatively regulate the expression of toll-like receptor-4 
(TLR4) and consequent activation of the TLR4-myeloid differentiation primary response 
(MYD)88-NF-kB signaling pathway, which plays a critical role in the recognition of pathogens 
and induction of the innate immune response against viral infections [25,26]. By counteracting 
cytokine storm statins may reduce the risk of myocardial injury and myocarditis in acute phases 
of COVID-19 [27]. In addition, statin-mediated anti-inflammatory effects may also promote 
stabilization of atherosclerotic plaques, thereby protecting from the occurrence of plaque rupture 
and cardiovascular events [8]. These effects provide an argument in support of statin continuation, 
even at high doses, for mitigating cardiovascular risk in the acute phases of COVID-19, especially 
in patients with manifest atherosclerotic CVD or CVD risk factors. Indeed, COVID-19-driven 
inflammation might promote atherosclerotic plaque instability [27]. In addition, although statin-
mediated stabilization of atherosclerotic plaques is known to be time-dependent, there are reports 
showing that some modulation of inflammation and some reduction of plaque remodelling may be 
obtained also after a short period of treatment with high doses of statins [28,29]. However, it should 
be emphasized that they are currently lacking clinical studies showing a significant impact of statin 
therapy in reduction of incident cardiovascular events in COVID-19 patients.  
Statins can exert some direct antiviral activity [18,30]. By inhibiting cholesterol synthesis, they 
can reduce the intracellular availability of a crucial compound for the viral cell cycle [31]. Indeed, 
the presence of cholesterol-rich subdomains on the plasma membrane of host cells, namely lipid 
rafts, is crucial for viral fusion and entry [18,30]. Furthermore, through cholesterol-dependent 
mechanisms, statins can inhibit the isoprenylation of different proteins (e.g., RhoA, Rac, and 
Cdc42), which are critical downstream molecules regulating viral cell cycle [18,30]. To date, a 
number of observational studies have suggested that statin therapy can reduce the risk of various 
severe complications and mortality in patients admitted with Middle East respiratory syndrome 
coronavirus (MERS-CoV) infection and influenza [32-35]. Therefore, it is possible that the 
beneficial effects of statin therapy as an add-on treatment in viral infections could be extended to 
COVID-19. To this regard, it should be considered that a peculiar antiviral mechanism of action 
of statins against COVID-19 might consist of inhibition of SARS-CoV-2 entry into host cells due 
to the binding of its main protease [36]. Nonetheless, whether statin therapy may reduce the risk 
of SARS-CoV-2 infection still needs to be investigated. 
5 
 
Statins have well-known protective effects against endothelial dysfunction and injury [19-21]. Due 
to their ability to upregulate ACE2 signaling pathways via epigenetic histone modifications, statins 
might exert some beneficial effects in terms of endothelial protection in the supportive therapy of 
COVID-19 patients [37]. Indeed, high levels of ACE2 on pulmonary endothelium have been 
associated with reduced severity of ARDS [38]. In addition, by promoting endothelial repair statins 
might counteract SARS-CoV-2-induced endothelitis in lungs as a direct consequence of both 
infection of endothelial cells and the host inflammatory response [39,40], thereby potentially 
accelerating recovery from ARDS. 
By inhibiting the activation of coagulation cascade and platelet function as well as increasing 
fibrinolytic activity, statins can exert antithrombotic effects [22] (Figure 2). Specifically, different 
statins have been shown to directly interfere with tissue factor expression, thrombin generation, 
fibrinogen cleavage, factor V and factor XIII activation, endothelial thrombomodulin expression, 
and platelet activation [22]. In addition, some inhibitory activity of statins on thrombus formation 
has been ascribed to their ability to modulate endothelial function and inflammatory response [22] 
(Figure 2). Arterial and venous thromboembolic events have been described as typical clinical 
features of severe COVID-19 [6-8]. Therefore, albeit being still not proved, it is plausible that 
statins might be useful to improve clinical outcomes of COVID-19 by reducing the incidence of 
COVID-19-related coagulopathy.  
To date, most of available data from clinical studies support the protective effect of statins against 
SARS-CoV-2 infection. Indeed, a number of retrospective studies have shown lower inflammatory 
parameters, decreased incidence of severe clinical manifestations or reduced mortality rates in 
COVID-19 patients under statin treatment as compared to those not taking statins [41,42]. 
However, consistent evidence from prospective studies is not currently available. In addition, two 
recent meta-analyses of observational studies exploring the impact of statin therapy on COVID-
19 outcomes have reported contrasting results [43,44]. Therefore, clinical trials investigating this 
issue are eagerly awaited. 
Against the hypothesis of a clinical benefit of statin use in COVID-19 patients, some safety 
concerns need to be taken into account. The main doubt about the beneficial effects of statins as 
add-on therapy in COVID-19 may be raised when considering the possible detrimental impact of 
reduced low-density lipoprotein (LDL) cholesterol levels on COVID-19 prognosis, as suggested 
by some retrospective studies [45,46]. However, reverse causality (i.e., viral infection as a cause 
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of LDL cholesterol reduction) instead of causality (i.e., LDL cholesterol reduction as a factor 
promoting viral infection) might explain the association between LDL cholesterol and severe 
COVID-19 manifestations [47]. This could distract from refuting the potential benefits of statin 
treatment in this clinical setting. 
Additional safety concerns may be raised considering the ability of statins to upregulate the 
expression of angiotensin-converting enzyme 2 (ACE2), which mediates SARS-CoV-2 entry into 
host cells [37,48]. However, such an effect may be clinically not significant if we assume that viral 
load is not necessarily related to the disease severity. Moreover, soluble ACE2 may bind to SARS-
CoV-2, preventing it from fusion with the membrane of host cells and, therefore, inhibiting viral 
replication [48].  
Another issue is represented by the risk of statin-related myotoxicity and hepatotoxity, which may 
be increased by drug-to-drug interactions between statins and antiviral, antiretroviral, antiparasitic, 
and antirheumatic drugs as well as antibiotics (mainly macrolides) that may be concomitantly 
administered to COVID-19 patients [49]. In some cases, either discontinuation of statin therapy or 
continuation with caution and at lower doses are possible options [49]. Nonetheless, when statin 
discontinuation is required, other lipid-lowering therapies could be considered, especially in 
patients at high CVD risk, which are more prone to undergo COVID-19 complications [49,50].  
An additional reason for caution about statin therapy in COVID-19 patients may be the possible 
statin-mediated increase of lipoprotein(a), which is known to exert an anti-fibrinolytic activity by 
controlling the activity of plasminogen activators [51]. However, it should be emphasized that 
statin-mediated increasing effect on lipoprotein(a) is not consistent and in some cases may be not 
significant [52,53]. Therefore, it remains uncertain as to whether an increased thrombotic risk may 
be expected by statin impact on lipoprotein(a) levels in COVID-19 patients.  
Further concerns are related to the observation that treatment with high-potency statins may be 
associated with an increased risk of incident type 2 diabetes, especially in obese patients [54]. 
Indeed, diabetes is a significant predictor of COVID-19 severe clinical manifestations. However, 
the  risk of developing insulin resistance with initiation of statin therapy is relatively low according 
to available data [55]. Therefore, whether statin-induced diabetes may be a reason to discourage 
statin use in COVID-19 patients is questionable.  
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Finally, the benefit-risk balance of statin therapy should be carefully evaluated in older patients 
with COVID-19. Indeed, beyond being at higher risk of poor prognosis, these patients are also at 
higher risk of statin-related adverse effects [56].  
Overall, available data and hypotheses based on biological plausibility do not support the notion 
that statin therapy may worsen the prognosis of patients with COVID-19. Conversely, they suggest 
that some clinical benefits in COVID-19 patients may derive from statin-mediated cholesterol-
lowering and pleiotropic effects. To this regard, although no clinical studies are currently available 
clearly showing that statins can reduce the incidence of cardiovascular events in COVID-19 
patients, evidence is emerging showing a possible benefit from statin therapy in reduction of 
COVID-19 severity and mortality. Therefore, the continuation of statin therapy in COVID-19 
patients should be considered [49,57]. Further, despite a current lack of direct information in 
COVID-19 subjects, observational and interventional studies appear warranted to establish both 
the efficacy and safety of de novo initiation of statin therapy as add-on treatment for the 
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Figure 1. Potential cellular pathways modulated by statins in SARS-CoV-2 infection. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts strongly with the human 
angiotensin-converting enzyme 2 (ACE2), allowing the virus to enter host cells, including 
endothelial and epitelial cells. Statins can upregulate the expression of ACE2 on the surface of 
endothelial and epithelial cells. Recognition of SARS-CoV-2 by Toll-like receptors (TLRs) on the 
surface of leukocyes activates the MYD88–NF-κB pathway and the innate immune response of 
the host, with the release of proinflammatory mediators. Statins can inhibit the MYD88–NF-κB 
proinflammatory pathway and the production of inflammatory cytokines. Statins can exert anti-
thrombotic effects by reducing the expression of tissue factor on activated endothelial cells and 
decreasing the cytosolic phospholipase A2 (cPLA2)-induced thromboxane A2 (TXA2) synthesis 
by platelets. Statins could reduce cholesterol content in the plasma membrane of SARS-CoV-2 
host cells, thereby destabilizing viral replication phases. Through all these mechanisms, statins 
might prove beneficial effects in COVID-19 patients. 
 
Figure 2. The possible statin-mediated modulation of SARS-CoV-2 infection pro-thrombotic 
profile. Endothelial activation and release of pro-inflammatory cytokines induced by SARS-CoV-
2 (1) lead to increased expression of adhesion molecules (ICAM-1, P-selectins, von Willebrand 
factor, αvβ3) and further release of proinflammatory cytokines (2), promoting the recruitment of 
platelets and leukocytes (3). Activated endothelial cells also express tissue factor, which promotes 
the activation of factor VII, factor Xa, and the generation of thrombin (4). Thrombin cleaves 
fibrinogen into fibrin (5), which is crucial for thormbus formation (6). Pro-inflammatory mediators 
may also activate the coagulation cascade and influence platelet activation, promoting accelerated 
thrombus formation (7). Statins can inhibit the release of proinflammatory cytokines by endothelial 
cells, as well as the activation of coagulation cascade. Also, statins might inhibit SARS-CoV-2 
entry into endothelial cells expressing ACE2 and subsequent endothelial activation.  
